We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

By LabMedica International staff writers
Posted on 27 May 2024
Print article
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management. In light of the COVID-19 pandemic, there have been significant advancements in laboratory medicine, enhancing the testing capabilities for respiratory viruses. These advancements include the use of diverse sample types and the introduction of various new testing methods. However, these developments have also created a need for greater educational efforts on how best to utilize these novel testing options. Addressing this need, a new guidance document has been released, offering expert advice on essential aspects of clinical testing for respiratory viral infections, aiming to maximize the benefits of recent technological advances in this rapidly evolving field.

This guidance has been formed by a multidisciplinary team of clinical microbiologists and infectious disease clinicians convened by the Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC, Washington, D.C., USA), with endorsement from the Pan American Society for Clinical Virology. Reflecting the latest insights from COVID-19 and other respiratory virus research, the document advocates for the use of nasopharyngeal samples for upper respiratory tract infections and suggests employing nucleic acid amplification testing whenever feasible. It emphasizes that the interpretation of viral load results should be considered alongside clinical symptoms.

Moreover, the guidance underlines the importance of diagnostic stewardship in respiratory virus testing, which is crucial for ensuring accurate, clinically relevant outcomes while also conserving laboratory resources. The document also introduces a decision-making algorithm designed to help laboratories identify the most suitable tests for specific cases of respiratory virus infection. This algorithm takes into account whether patients are symptomatic, immunocompromised, and whether a positive test result would alter disease management strategies.

“The current guidance document is the authors’ expert opinion based on the preponderance of available evidence to address key questions related to best practices for laboratory diagnosis of respiratory viral infections,” wrote the guidance document authors Drs. Gregory J. Berry, Tulip A. Jhaveri, Paige M.K. Larkin, Heba Mostafa, and N. Esther Babady. “Laboratorians should remain alert and involved to provide guidance on managing testing and the information obtained from a wider range of testing settings.”

Related Links:
ADLM Guidance Document on Laboratory Diagnosis of Respiratory Viruses


Print article

Channels

Molecular Diagnostics

view channel
Image: The blood test uses AI to predict Parkinson’s seven years before onset of symptoms (Photo courtesy of Kateryna Kon/Shutterstock)

AI-Powered Blood Test Predicts Parkinson's Seven Years before Symptoms Appear

Parkinson’s disease is currently the fastest-growing neurodegenerative disorder worldwide, affecting nearly 10 million people globally. It is a progressive disease caused by the deterioration and death... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.